819-827
Original Article
Open AccessEfficacy of CR3294, a new benzamidine derivative, in the prevention of 5-fluorouracil-induced gastrointestinal mucositis and diarrhea in mice
Ornella Letari, Catherine Booth, Albino Bonazzi, Paolo Garofalo and Francesco Makovec, et al.
829-835
Original Article
A phase I trial of lomeguatrib and irinotecan in metastatic colorectal cancer
A. Sabharwal, P. G. Corrie, R. S. Midgley, C. Palmer and J. Brady, et al.
837-844
Original Article
Sorafenib plus octreotide is an effective and safe treatment in advanced hepatocellular carcinoma: multicenter phase II So.LAR. study
Salvatore Del Prete, Liliana Montella, Michele Caraglia, Luigi Maiorino and Gregorio Cennamo, et al.
845-850
Original Article
A phase II study of fenretinide in patients with hormone refractory prostate cancer: a trial of the Cancer Therapeutics Research Group
M. M. Moore, M. Stockler, R. Lim, T. S. K. Mok and M. Millward, et al.
851-859
Original Article
Syl611, a novel semisynthetic taxane derivative, reverses multidrug resistance by p-glycoprotein inhibition and facilitating inward transmembrane action
Yi Zhang, Hongyan Li, Hongbo Wang, Fuqin Su and Runjiang Qu, et al.
861-868
Original Article
A phase-I trial of pemetrexed plus carboplatin in recurrent ovarian cancer
Jalid Sehouli, Oumar Camara, Sven Mahner, Thomas Bauknecht and Werner Lichtenegger, et al.
869-880
Original Article
The Bcl-2 inhibitor ABT-263 enhances the response of multiple chemotherapeutic regimens in hematologic tumors in vivo
Scott Ackler, Michael J. Mitten, Kelly Foster, Anatol Oleksijew and Marion Refici, et al.
881-888
Original Article
Open AccessVoreloxin, a first-in-class anticancer quinolone derivative, acts synergistically with cytarabine in vitro and induces bone marrow aplasia in vivo
Caroline D. Scatena, Jeffrey L. Kumer, Jennifer P. Arbitrario, Anthony R. Howlett and Rachael E. Hawtin, et al.
889-897
Original Article
Phase II study with fractionated schedule of docetaxel and cisplatin in patients with advanced non-small cell lung cancer
Jung Hye Kwon, Jung Han Kim, Jung-Ae Lee, Hyun Chun Shin and Hyo Jung Kim, et al.
899-911
Original Article
Se-methylselenocysteine sensitizes hypoxic tumor cells to irinotecan by targeting hypoxia-inducible factor 1α
Sreenivasulu Chintala, Károly Tόth, Shousong Cao, Farukh A. Durrani and Mary M. Vaughan, et al.
913-918
Original Article
Phase II study of S-1 and docetaxel for previously treated patients with locally advanced or metastatic non-small cell lung cancer
Kazuhiro Yanagihara, Kenichi Yoshimura, Miyuki Niimi, Hiroyasu Yasuda and Takahiko Sasaki, et al.
919-925
Original Article
Open AccessA general process for the development of peptide-based immunoassays for monoclonal antibodies
Ana B. Sanchez, Tammy Nguyen, Rhanika Dema-Ala, Andrew C. Kummel and Thomas J. Kipps, et al.
927-933
Original Article
Plasma and cerebrospinal fluid pharmacokinetics of topotecan in a phase I trial of topotecan, tamoxifen, and carboplatin, in the treatment of recurrent or refractory brain or spinal cord tumors
Robert J. Morgan, Timothy Synold, Adam Mamelak, Dean Lim and Zaid Al-Kadhimi, et al.
935-943
Original Article
Phase 1 study of the investigational, oral angiogenesis inhibitor motesanib in Japanese patients with advanced solid tumors
Yasuhito Fujisaka, Yasuhide Yamada, Noboru Yamamoto, Toshio Shimizu and Yutaka Fujiwara, et al.
945-952
Original Article
Enhancement of cisplatin sensitivity by NSC109268 in budding yeast and human cancer cells is associated with inhibition of S-phase progression
Dilip Jain, Nila Patel, Melanie Shelton, Alakananda Basu and Rouel Roque, et al.
953-959
Original Article
Down-regulation of lipids transporter ABCA1 increases the cytotoxicity of Nitidine
Hironori Iwasaki, Takafumi Okabe, Kensaku Takara, Yasuhiko Yoshida and Kaoru Hanashiro, et al.
961-968
Original Article
Phase II study of pemetrexed in patients with advanced neuroendocrine tumors
Jennifer A. Chan, Andrew X. Zhu, Keith Stuart, Pankaj Bhargava and Craig C. Earle, et al.
969-972
Original Article
Increased anticoagulant activity of warfarin used in combination with doxifluridine
Masaru Nakajima, Tomoo Genda, Mayu Suehira, Hiroki Satoh and Akiko Miki, et al.
973-980
Original Article
The maximum tolerated dose and biologic effects of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP) in combination with irinotecan for patients with refractory solid tumors
Brian S. Choi, Dona B. Alberti, William R. Schelman, Jill M. Kolesar and James P. Thomas, et al.
981-986
Original Article
Antitumor effects of recombinant human Interleukin-6 on mouse bladder carcinoma through Fas-mediated apoptosis
Chuan-gang Li, Mo-lin Li, Xiao-hong Shu, Yong-ji Liu and Wen-sen Wu
987-992
Clinical Trial Report
A phase II study of combination therapy with irinotecan and S-1 (IRIS) in patients with advanced colorectal cancer
Manabu Shiozawa, Makoto Akaike, Nobuhiro Sugano, Kazuhito Tsuchida and Naoto Yamamoto, et al.
993-998
Short Communication
Relationship among pharmacokinetics and pharmacodynamics of fenretinide and plasma retinol reduction in neuroblastoma patients
Franca Formelli, Elena Cavadini, Roberto Luksch, Alberto Garaventa and Valentina Appierto, et al.
999-1003
Short Communication
C6 ceramide potentiates curcumin-induced cell death and apoptosis in melanoma cell lines in vitro
Teng Yu, Jinchao Li and Hui Sun